DAVID RUDLOFF — Lobbyist Profile | Poliscope

DAVID RUDLOFF

Filings

1,339

Clients

129

Firms

Years active

2018–2026

Associated filing income

$31,638,250

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY	37	2020–2025
ACCURAY INCORPORATED	35	2018–2026
U.S. RENAL CARE	32	2019–2026
HARMONY BIOSCIENCES, LLC	29	2020–2026
STERIS CORPORATION	29	2020–2026
ARDELYX INC	28	2020–2026

Lobbying firms

Firm	Filings	Years
JEFFREY J. KIMBELL & ASSOCIATES, INC.	1,339	2018–2026

Bills explicitly cited in this lobbyist’s assigned issues (100)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Original LDA source filings (100)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

ANI

Animals

Issues related to animal health

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Source: Senate LDA

Show 96 more cited filings

H.R. 2527

Early Detection of Vision Impairments for Children Act of 2025

Client: GLAUKOS CORPORATION (FKA AVEDRO, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

H.R. 2527, the Early Detection of Vision Impairments for Children Act

H.R. 6214

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 6214

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 6214

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 2730

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 2730

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 2730

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 2199

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 2666

CBO Scoring Accountability Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 6214

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

S. 1173

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

S. 2730

Kidney Care Access Protection Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 5074

Kidney PATIENT Act of 2023

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act

H.R. 5074

Kidney PATIENT Act of 2023

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 5018

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

S. 5018

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

S. 5018

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 7389

MVP Act

Client: INSTITUTE FOR GENE THERAPIES · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

H.R. 1350

Cameron’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

H.R. 1350

Cameron’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.

H.R. 1350

Cameron’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.

H.R. 1350

Cameron’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

H.R. 1805

Leo’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

H.R. 1805

Leo’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.

H.R. 1805

Leo’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act.

H.R. 1805

Leo’s Law

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.

H.R. 2630

Safe Step Act

Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions

H.R. 2630

Safe Step Act

Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2666

Medicaid VBPs for Patients Act

Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Value-based pricing arrangements; MVP Act - HR 2666

H.R. 2673

American Innovation and R&D Competitiveness Act of 2023

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the development of therapies for rare diseases and sleep disorders; drug pricing; Medicare Part D redesign; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, The Rare Disease Clinical Trials Pandemic Disruption Act. Reauthorization of the Pandemic and All-Hazards Preparedness Act. H.R. 2673, The American Innovation and R&D Competitiveness Act.

H.R. 5539

ORPHAN Cures Act

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.

H.R. 6860

Restore Protections for Dialysis Patients Act

Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis

H.R. 830

HELP Copays Act

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act

H.R. 830

HELP Copays Act

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

H.R. 972

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression

S. 1375

HELP Copays Act

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act

S. 1375

HELP Copays Act

Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

S. 312

Outpatient Surgery Quality and Access Act of 2023

Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.

Open original LDA filing ↗

Cited source text

Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act

Show 96 more original filings

ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to tariffs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues regarding coding and reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare coverage of histotripsy procedures

HCR

Health Issues

Issues related to Medicare coverage of histotripsy procedures

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicare inpatient reimbursement for medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

ANI

Animals

Educate policymakers about the veterinary medicine landscape

CSP

Consumer Issues/Safety/Products

Educate policymakers about the veterinary medicine landscape

LBR

Labor Issues/Antitrust/Workplace

Educate policymakers about the veterinary medicine landscape

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Issues related to Medicare/Medicaid reimbursement

HCR

Health Issues

Issues related to Diabetes care

DEF

Defense

Issues related to the Tricare Program

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to health screening

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to regulation of cell therapies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the No Surprises Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicare reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs

HCR

Health Issues

Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience

Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

INDIVIOR INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to substance use disorder

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AGIOS PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to prescription drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEUSPERA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GENETIX BIOTHERAPEUTICS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to FDA regulation of rare disease therapies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

OPUS GENETICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to FDA regulation of gene therapies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ATEA PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to hepatitis C and prescription drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ACME UNITED CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues related to trade

HCR

Health Issues

Issues related to medical products

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AVALON HEALTHCARE SOLUTIONS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to diagnostic laboratory services

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to cell therapy development

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

THE ALLERGY & ASTHMA ALLIANCE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

issues related to allergy & asthma reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MOBIA MEDICAL, INC (FKA MICROTRANSPONDER) via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CAPRICOR via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to rare disease therapeutic development

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ONE CALL, CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the Federal Employees Compensation Act (FECA)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHATHOM PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to drug approval

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

RECOR MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to coverage of medical devices

MMM

Medicare/Medicaid

Issues related to coverage of medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SUMMIT BEHAVIORAL HEALTHCARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to behavioral healthcare companies and substance use services

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ALEXION PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Medicare and Medicaid reimbursements for pharmaceuticals

HCR

Health Issues

Issues related to pharmaceuticals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INSMED, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare reimbursement of pharmaceutical products

HCR

Health Issues

General Issues of interest to pharmaceutical companies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HARROW INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare rebates

HCR

Health Issues

Issues related to the regulation of pharmaceuticals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

KENDAL NUTRICARE LTD via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

AGR

Agriculture

Issues related to formula

TRD

Trade (domestic/foreign)

Issues related to tariffs

Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $9,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

issues related to tissue products

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to pharmaceutical drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to approval of combination products

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $7,500Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to pharmaceutical drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ILLUMINA, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $18,750Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

NIH Funding

HCR

Health Issues

Issues related to health care diagnostics

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to implementation of the Inflation Reduction Act of 2022; Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

DEF

Defense

Issues Related to Defense and Human Performance

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to pharmaceutical drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to FDA and rare diseases

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

issues related to the pharmaceutical industry

MMM

Medicare/Medicaid

issues related to Medicare drug reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

General Issues of interest to pharmaceutical companies

MMM

Medicare/Medicaid

Medicare reimbursement of pharmaceuticals

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

medical device manufacturing, servicing, and sterilization issues; FDA modernization

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $75,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to regulation of prescription drugs and biologics

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

issues related to senior health care

HOU

Housing

issues related to senior housing

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

General FDA issues related to orphan drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the development and approval of therapies for rare diseases

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

HCR

Health Issues

Matters affecting Medicare/Medicaid Issues

MMM

Medicare/Medicaid

Matters affecting Medicare/Medicaid Issues

PHA

Pharmacy

Matters affecting Medicare/Medicaid Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to medication affordability and access

MMM

Medicare/Medicaid

Issues related to Medicare ESRD benefit and chronic kidney disease management

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INSTITUTE FOR GENE THERAPIES via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to the regulation of gene therapies; newborn screening; FDA appropriations

MMM

Medicare/Medicaid

Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $36,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to pharmaceutical drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

health care coverage

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

U.S. RENAL CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $50,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicare policies impacting ESRD; Restore Protections for Dialysis Patients Act - H.R.2199/S.1173; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; Kidney Care Access Protection Act - H.R. 6214/S.2730

Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

ACCURAY INCORPORATED via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

issues related to tariffs and trade

MMM

Medicare/Medicaid

Issues related to Medicare payment for/access to radiation therapy services

Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to diabetes and cardiovascular disease

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GLAUKOS CORPORATION (FKA AVEDRO, INC.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

issues related to medical device and drug coverage and reimbursement

HCR

Health Issues

H.R. 2527, the Early Detection of Vision Impairments for Children Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

TERUMO BCT via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues related to supply chain constraints

MMM

Medicare/Medicaid

Issues related to apheresis access and reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SSI GROUP via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to health IT and medical records

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

LIVANOVA USA INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $30,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to epilepsy; issues related to telehealth

MMM

Medicare/Medicaid

Medicare beneficiary access to procedures performed in ambulatory surgical centers; Medicare beneficiary access to treatments for depression and epilepsy

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

IBA PROTON THERAPY via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

issues related to coverage of proton therapy

MMM

Medicare/Medicaid

issues related to coverage of proton therapy

FLOREO INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to treatment of autism spectrum disorder

ASTELLAS PHARMA US via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

issues related to pharmaceutical drugs

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INNOVAGE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · 3T

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

issues related to the PACE program

MMM

Medicare/Medicaid

issues relevant to the PACE program

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

HANSA BIOPHARMA AB via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies

HCR

Health Issues

Issues related to organ transplants; Medicare issues relevant to pharmaceutical companies

ARTERA INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device

HCR

Health Issues

Issues related to cancer screening, diagnosis and digital pathology; Medicare reimbursement of laboratory developed tests and software as a medical device

ARGENTA US HOLDINGS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

ANI

Animals

Issues related to animal health

GOSSAMER BIO, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to FDA regulation of pharmaceuticals

CARA MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MMM

Medicare/Medicaid

Issues related to Medicare reimbursement for medical devices

HCR

Health Issues

Issues related to Medicare reimbursement for medical devices

CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare inpatient reimbursement for medial devices

SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · 3T

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

AGR

Agriculture

Issues related to hemp

HCR

Health Issues

Issues related to hemp

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · 3T

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to the development and commercialization of brain-computer interfaces

MMM

Medicare/Medicaid

Issues related to coverage of medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ARCUTIS BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

TAR

Tariff (miscellaneous tariff bills)

Issues related to tariffs

HISTOSONICS, INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medicare coverage of histotripsy procedures

MMM

Medicare/Medicaid

Issues related to Medicare coverage of histotripsy procedures

FLEX VASCULAR via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

issues regarding coding and reimbursement

JCYTE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RA

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to cell therapy development.

PROVERUM MEDICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to medical devices

CLEARFLOW, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Medicare inpatient reimbursement for medical devices

COALITION FOR AFFORDABLE PET CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

CSP

Consumer Issues/Safety/Products

Educate policymakers about the veterinary medicine landscape

LBR

Labor Issues/Antitrust/Workplace

Educate policymakers about the veterinary medicine landscape

ANI

Animals

Educate policymakers about the veterinary medicine landscape

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEURALINK CORP. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to the development and commercialization of brain-computer interfaces

MMM

Medicare/Medicaid

Issues related to coverage of medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MANNKIND CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

DEF

Defense

Issues related to the Tricare Program

MMM

Medicare/Medicaid

Issues related to Medicare/Medicaid reimbursement

HCR

Health Issues

Issues related to Diabetes care

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

GAURDANT HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to health screening

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ATARA BIOTHERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to regulation of cell therapies

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INDEMED via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to the No Surprises Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MAGNOLIA MEDICAL TECHNOLOGIES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to medical devices

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

MAGNUS MEDICAL, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

HCR

Health Issues

Issues related to Medical Device Reimbursement

MMM

Medicare/Medicaid

Issues related to Medical Device Reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

COLOPLAST CORP via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Medicare reimbursement

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

RAYNER INTRAOCULAR LENSES LIMITED via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Issues related to Reauthorization of the NO PAIN Act ; Medicare issues related to a non-opioid product

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

ORCHARD THERAPEUTICS NORTH AMERICA via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (3 issues)

MMM

Medicare/Medicaid

Matters affecting Medicare/Medicaid Issues

HCR

Health Issues

Matters affecting Medicare/Medicaid Issues

PHA

Pharmacy

Matters affecting Medicare/Medicaid Issues

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

SKY MARKETING CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

AGR

Agriculture

Issues related to hemp

HCR

Health Issues

Issues related to hemp

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

PAR HEALTH USA, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

TRD

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs

HCR

Health Issues

Issues related to domestic pharmaceutical manufacturing; Issues related to supply chain resilience

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INDIVIOR INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.

2026 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to substance use disorder

Filing targets: HOUSE OF REPRESENTATIVES, SENATE